VLS — Vita Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- AU$130.28m
- AU$105.98m
- AU$74.16m
- 99
- 73
- 88
- 97
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 42.5 | 46.5 | 57.1 | 66.9 | 74.2 |
Cost of Revenue | |||||
Gross Profit | 27.9 | 29.3 | 34.8 | 39.7 | 43.1 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 38 | 38.4 | 45.9 | 56.2 | 62.1 |
Operating Profit | 4.44 | 8.13 | 11.2 | 10.6 | 12 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.43 | 8.16 | 11.2 | 10.7 | 12.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3.09 | 5.86 | 8.25 | 7.34 | 9.08 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3.14 | 6.09 | 8.29 | 7.08 | 9.08 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3.14 | 6.09 | 8.29 | 7.08 | 9.08 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.057 | 0.116 | 0.156 | 0.131 | 0.166 |
Dividends per Share |